Takeda, Sucampo Of U.S. Locked In Marketing Dispute Over IBS Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and U.S.-based Sucampo Pharmaceuticals could be headed to an international arbitration court to settle a dispute over a marketing contract